

Company Number: 632665

New Beta Innovation Biopharmaceutical Ireland Limited

Abridged Unaudited Financial Statements

for the financial year ended 30 June 2025

New Beta Innovation Biopharmaceutical Ireland Limited

CONTENTS

	Page
Director's Responsibilities Statement	3
Balance Sheet	4
Notes to the Financial Statements	5 - 7

New Beta Innovation Biopharmaceutical Ireland Limited

DIRECTOR'S RESPONSIBILITIES STATEMENT

for the financial year ended 30 June 2025

The director is responsible for preparing the Director's Report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the director to prepare financial statements for each financial year. Under that law, the director has elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard, issued by the Financial Reporting Council. Under company law, the director must not approve the financial statements unless they is satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the director is required to:

- select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The director is responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Director's Report comply with the Companies Act 2014. They is also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

New Beta Innovation Biopharmaceutical Ireland Limited

BALANCE SHEET

as at 30 June 2025

	Notes	2025 €	2024 €
Current Assets			
Debtors	6	-	134
Creditors: amounts falling due within one year	7	(27,169)	(27,286)
Net Current Liabilities		(27,169)	(27,152)
Total Assets less Current Liabilities		(27,169)	(27,152)
Capital and Reserves			
Called up share capital presented as equity		1	1
Retained earnings		(27,170)	(27,153)
Equity attributable to owners of the company		(27,169)	(27,152)

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard.

I as Director of New Beta Innovation Biopharmaceutical Ireland Limited, state that -

(a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014,


(b) the company is availing itself of the exemption on the grounds that the conditions specified in section 359 are satisfied,

(c) the shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2),

(d) I acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of the Companies Act 2014 relating to financial statements so far as they are applicable to the company,

(e) the company has relied on the specified exemption contained in section 352 Companies Act 2014. The company has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014 and the small companies' regime.

Approved by the board on 16 February 2026 and signed on its behalf by:



Chi Heng Cheng
Director

New Beta Innovation Biopharmaceutical Ireland Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 June 2025

1. General Information

New Beta Innovation Biopharmaceutical Ireland Limited is a company limited by shares incorporated and registered in Ireland. The registered number of the company is 632665. The registered office of the company is The Black Church, St. Mary's Place, Dublin 7, D07 P4AX. The company has not started to trade. The financial statements have been presented in Euro (€) which is also the functional currency of the company.

2. Summary of Significant Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

Statement of compliance

The financial statements of the company for the financial year ended 30 June 2025 have been prepared in accordance with the provisions of FRS 102 Section 1A (Small Entities) and the Companies Act 2014.

Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" Section 1A, issued by the Financial Reporting Council.

The company qualifies as a small company as defined by section 280A of the Companies Act 2014 in respect of the financial year, and has applied the rules of the 'Small Companies Regime' in accordance with section 280C of the Companies Act 2014 and Section 1A of FRS 102.

Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

Employee benefits

The company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the company in an independently administered fund. The company also operates a defined benefit pension scheme for its employees providing benefits based on final pensionable pay. The assets of this scheme are also held separately from those of the company, being invested with pension fund managers.

Taxation and deferred taxation

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Balance Sheet date.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events have occurred at that date that will result in an obligation to pay more tax in the future, or a right to pay less tax in the future. Timing differences are temporary differences between the company's taxable profits and its results as stated in the financial statements.

Deferred tax is measured on an undiscounted basis at the tax rates that are anticipated to apply in the periods in which the timing differences are expected to reverse, based on tax rates and laws that have been enacted or substantively enacted by the Balance Sheet date.

New Beta Innovation Biopharmaceutical Ireland Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 June 2025

Foreign currencies

Monetary assets and liabilities denominated in foreign currencies are translated at the rates of exchange ruling at the Balance Sheet date. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated at the rates of exchange ruling at the date of the transaction. Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. The resulting exchange differences are dealt with in the Profit and Loss Account.

Ordinary share capital

The ordinary share capital of the company is presented as equity.

3. Going concern

The company's balance sheet shows an excess of liabilities over assets. Notwithstanding this, the financial statements have been prepared on a going concern basis. Having carefully considered the company's financial position, projections, restructuring plans and finance requirements for the next 12 months the director considers it appropriate to prepare the financial statements on a going concern basis.

4. Operating loss	2025	2024
	€	€
Operating loss is stated after charging/(crediting):		
(Profit)/loss on foreign currencies	(116)	198
	<u> </u>	<u> </u>

5. Employees

The average monthly number of employees, including director, during the financial year was 0, (2024 - 0).

6. Debtors	2025	2024
	€	€
Other debtors	-	1
Prepayments	-	133
	<u> </u>	<u> </u>
	<u> </u>	<u> </u>
	-	134

7. Creditors	2025	2024
Amounts falling due within one year	€	€
Amounts owed to group undertakings (Note 10)	27,169	-
Amounts owed to connected parties (Note 10)	-	27,286
	<u> </u>	<u> </u>
	<u> </u>	<u> </u>
	27,169	27,286

8. Profit and loss account

	2025	2024
	€	€
At 1 July 2024	(27,153)	(24,887)
Loss for the financial year	(17)	(2,266)
	<u> </u>	<u> </u>
At 30 June 2025	(27,170)	(27,153)

9. Capital commitments

The company had no material capital commitments at the financial year-ended 30 June 2025.

New Beta Innovation Biopharmaceutical Ireland Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 June 2025

10. Related party transactions

Bios Biotechnology Company Limited is a Hong Kong incorporated company and the 100% shareholder of New Alpha Innovation Biopharmaceutical Ireland Limited.

The following amounts are due to other connected parties:

	2025	2024
	€	€
New Beta Innovation Limited	-	27,286
	<u> </u>	<u> </u>

New Beta Innovation Limited is owned by the same parent company of the company, Wai Sang Dumas Chow holds a common directorship in both companies, New Beta Innovation Limited is a company incorporated in Hong Kong and trades in the research and development of bio-medical products.

Transactions and balances with group company:

	2025	2024
	€	€

Group Undertaking Creditors

Bios Biotechnology Company Limited	27,169	-
	<u> </u>	<u> </u>

11. Controlling interest

Bios Biotechnology Company Limited is the sole shareholder of the company. The parent company is incorporated in Hong Kong and Chen Zhao holds a common directorship between both companies. The ultimate controlling party is Chen Zhao.

12. Post-Balance Sheet Events

There have been no significant events affecting the company since the financial year-end.

13. Approval of financial statements

The financial statements were approved and authorised for issue by the board on 16 February 2026.